INDP
Income statement / Annual
Last year (2023), Indaptus Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Indaptus Therapeutics, Inc.'s net income was -$15.42 M.
See Indaptus Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$1,284.00 |
$1,781.00 |
$1,403.00 |
$852.00 |
$854,000.00 |
$859,000.00 |
$829,000.00 |
$701,000.00 |
$745,903.00 |
| Gross Profit |
-$1,284.00 |
-$1,781.00 |
-$1,403.00 |
-$852.00 |
-$854,000.00 |
-$859,000.00 |
-$829,000.00 |
-$701,000.00 |
-$745,903.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$7.62 M
|
$6.32 M
|
$2.52 M
|
$2.66 M
|
$26.66 M
|
$35.40 M
|
$24.30 M
|
$10.07 M
|
$4.09 M
|
| General & Administrative
Expenses |
$8.66 M
|
$8.59 M
|
$5.21 M
|
$944,248.00
|
$542,556.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing
Expenses |
$100,742.00
|
$0.00
|
$0.00
|
$0.00
|
$7.43 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$8.76 M
|
$8.59 M
|
$5.21 M
|
$944,248.00
|
$7.43 M
|
$7.07 M
|
$4.32 M
|
$3.07 M
|
$2.77 M
|
| Other Expenses |
$7.62 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$16.38 M |
$14.91 M |
$7.73 M |
$3.60 M |
$34.09 M |
$42.47 M |
$28.61 M |
$13.15 M |
$6.85 M |
| Cost And Expenses |
$16.38 M |
$14.91 M |
$7.73 M |
$3.60 M |
$34.95 M |
$43.33 M |
$29.44 M |
$13.85 M |
$7.60 M |
| Interest Income |
$0.00 |
$588,108.00 |
$17,722.00 |
$15,114.00 |
$330,000.00 |
$852,000.00 |
$286,000.00 |
$176,000.00 |
$44,785.00 |
| Interest Expense |
$0.00 |
$588,108.00 |
$0.00 |
$0.00 |
$15,000.00 |
$23,000.00 |
$17,000.00 |
$16,000.00 |
$0.00 |
| Depreciation &
Amortization |
$1,284.00
|
$1,781.00
|
$1,403.00
|
$852.00
|
$854,000.00
|
$859,000.00
|
$829,000.00
|
$701,000.00
|
$745,903.00
|
| EBITDA |
-$16.38 M
|
-$14.91 M
|
-$7.73 M
|
-$3.60 M
|
-$34.09 M
|
-$42.47 M
|
-$28.61 M
|
-$13.15 M
|
-$6.85 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$955,003.00
|
$588,108.00
|
$17,722.00
|
$15,114.00
|
-$12.02 M
|
-$112,000.00
|
$558,999.00
|
$484,000.00
|
$423,396.00
|
| Income Before Tax |
-$15.42 M |
-$14.32 M |
-$7.71 M |
-$3.58 M |
-$46.96 M |
-$43.44 M |
-$28.88 M |
-$13.36 M |
-$7.18 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
-$16.38 M |
-$588,108.00 |
-$17,722.00 |
-$15,114.00 |
$638,000.00 |
$103,000.00 |
$29,000.00 |
$0.00 |
-$4.00 |
| Net Income |
-$15.42 M |
-$13.73 M |
-$7.69 M |
-$3.57 M |
-$47.60 M |
-$43.54 M |
-$28.91 M |
-$13.36 M |
-$7.18 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-1.84 |
-1.66 |
-1.88 |
-7.34 |
-112.74 |
-111.67 |
-130.96 |
-93.38 |
-73.7 |
| EPS Diluted |
-1.84 |
-1.66 |
-1.88 |
-7.34 |
-112.74 |
-111.67 |
-130.96 |
-93.38 |
-73.7 |
| Weighted Average Shares
Out |
$8.40 M
|
$8.26 M
|
$4.09 M
|
$486,168.00
|
$422,200.00
|
$389,912.00
|
$220,750.00
|
$143,100.00
|
$97,387.00
|
| Weighted Average Shares
Out Diluted |
$8.40 M
|
$8.26 M
|
$4.09 M
|
$486,168.00
|
$422,200.00
|
$389,912.00
|
$220,750.00
|
$143,100.00
|
$97,387.00
|
| Link |
|
|
|
|
|
|
|
|
|
